Welcome readers,
We couldn't resist—with all eyes turning to Munich for next week's Expo Real, we're focusing entirely on deals this week. Consider it our way of capturing the deal-making energy as the industry's biggest networking event approaches. From San Sebastian to Manchester, Berlin to Leipzig, we're tracking the transactions that matter: 8 in Germany, 6 in the UK, 2 each in the Netherlands and Spain, and 1 each in France and Ireland.
We also answer this question: what does €10–100 million actually get you in this market?
🔒 Paying subscribers get 20 deals • Everyone else can explore 3 of them → Get full access by subscribing here.
— Stephen Ryan (connect with me on LinkedIn)
🔍 Do you need deeper insights into life sciences real estate?
In addition to our regular updates, we offer bespoke research and strategic analysis for investors and developers in the life sciences sector. Whether you’re evaluating an acquisition, tracking market trends, or need a custom report, our team can help you make informed decisions.
Get in touch to discuss how we can support your next project.
Featured article of the week
What does €10–100 million buy in European life sciences real estate?
Analysis of 114 transactions totalling €4.4 billion reveals investment patterns in European life sciences real estate
Deals
FRANCE PARIS
Kadans Science Partner has signed a lease with Orano Med for headquarters and R&D laboratory space at The Hive within Campus Grand Parc. The Orano Group subsidiary, which specialises in targeted alpha therapies in oncology, will relocate to the 25,000 sq m building in 2026 following fit-out works. The research laboratory is scheduled for commissioning in the first half of 2026 and will focus on chemical vector development for targeted alpha therapy applications. The site forms part of the Paris Saclay Cancer Cluster biocluster.
GERMANY BERLIN
Berlin-based contract development and manufacturing organisation (CDMO) ProBioGen AG has been chosen to design, build, and operate the GMP manufacturing unit at the new Berlin Center for Gene and Cell Therapies (BC GCT). The 4,600 sq m facility will focus on process development and GMP production of advanced therapy medicinal products (ATMPs). BC GCT represents a joint initiative between Charité - Universitätsmedizin Berlin, Bayer, and the Berlin Institute of Health at Charité (BIH), positioning itself as a European hub for translational medicine. The centre will combine GMP-certified manufacturing capabilities with a startup incubator featuring laboratory space, offices, and mentoring resources.
Would you like instant access to 1,200+ deals like these? Our data tool lets you filter, sort and search European life sciences transactions spanning 24 countries—whether you're tracking a single city or spotting market patterns others miss.
GERMANY DARMSTADT
Merck has opened its Launch and Technology Center at its Darmstadt headquarters following a €160 million investment in the site. The facility will become fully operational in 2026 and is designed to serve as a bridge between research and commercial manufacturing for small molecule-based therapies. The ceremonial opening was attended by Merck Group chief executive Belén Garijo and healthcare chief executive Danny Bar-Zohar. The centre will focus on accelerating the development of therapies for patients with unmet medical needs.
👇 As a free member, you get access to three deals for free.
Upgrade now to access the full list (16 more deals this week).
